Background: The functional changes that occur over time in the liver following Y-radioembolization (RE) using personalized dosimetry (PD) remain to be investigated.

Methods: November 2016-October 2019: we retrospectively included hepatocellular carcinoma (HCC) patients treated by Y-glass RE using PD, who underwent hepatobiliary scintigraphy (HBS) at baseline and at 15 days, 1, 2, 3, and 6 months after RE.

Results: There were 16 patients with unilobar disease (100%) included, and 64 HBS were performed. Whole liver function significantly decreased over time. The loss was maximal at 2 weeks: -32% ( = 0.002) and remained below baseline at 1 (-15%; = 0.002), 2 (-25%; < 0.001), and 3 months (-16%; = 0.027). No radioembolization-induced liver disease was observed. Treated liver function strongly decreased to reach -64% ( < 0.001) at 2 months. Nontreated liver function decreased at 2 weeks (-21%; = 0.027) and remained below baseline before reaching +20% ( = 0.002) and +59% ( < 0.001) at 3 and 6 months, respectively. Volumetric and functional changes exhibited parallel evolutions in the treated livers ( = 0.01) but independent evolutions in the nontreated livers ( = 0.08).

Conclusion: RE using PD induces significant regional changes in liver function over time. As early as 15 days following RE, both the treated and nontreated livers showed a decreased function. Nontreated liver function recovered after 3 months and greatly increased afterwards.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224303PMC
http://dx.doi.org/10.3390/diagnostics11060931DOI Listing

Publication Analysis

Top Keywords

liver function
20
nontreated liver
12
function decreased
12
0001 months
12
hepatobiliary scintigraphy
8
personalized dosimetry
8
treated nontreated
8
liver
8
functional changes
8
remained baseline
8

Similar Publications

Pumpkin extract has been shown to alleviate hyperglycemic symptoms by improving glucose metabolism disorders. However, the specific active components responsible for its hypoglycemic effects and the underlying molecular mechanisms remain unclear. In this study, db/db mice underwent a 4-week dietary intervention with two pumpkin flours (PF1 and PF2), total dietary fiber (TDF), soluble dietary fiber (SDF), and insoluble dietary fiber (IDF), with acarbose serving as a positive control.

View Article and Find Full Text PDF

Appetite, as the internal drive for food intake, is often dysregulated in a broad spectrum of conditions associated with over- and under-nutrition across the lifespan. Appetite regulation is a complex, integrative process comprising psychological and behavioral events, peripheral and metabolic inputs, and central neurotransmitter and metabolic interactions. The microbiota-gut-brain axis has emerged as a critical mediator of multiple physiological processes, including energy metabolism, brain function, and behavior.

View Article and Find Full Text PDF

Molecular docking to investigate HLA-associated idiosyncratic drug reactions.

Drug Metab Rev

January 2025

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.

Idiosyncratic drug reactions (IDRs) pose severe threats to patient health. Unlike conventionally dose-dependent side effects, they are unpredictable and frequently manifest as life-threatening conditions, such as severe cutaneous adverse reactions (SCARs) and drug-induced liver injury (DILI). Some HLA alleles, such as , , and , are known risk factors for adverse reactions induced by multiple drugs.

View Article and Find Full Text PDF

Mice with genetic ablation of PI3Kγ are protected from diet-induced obesity. However, the cell type responsible for PI3Kγ action in obesity remains unknown. We generated mice with conditional deletion of PI3Kγ in neurons using the nestin promoter to drive the expression of the Cre recombinase (PI3Kγ mice) and investigated their metabolic phenotype in a model of diet-induced obesity.

View Article and Find Full Text PDF

In this article, we comment on an article published in a recent issue of the . We specifically focus on the roles of human leukocyte antigen (HLA) and donor-specific antibodies (DSAs) in pediatric liver transplantation (LT), as well as the relationship between immune rejection after LT and DSA. Currently, LT remains the standard of care for pediatric patients with end-stage liver disease or severe acute liver failure.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!